0001140361-21-006730.txt : 20210301
0001140361-21-006730.hdr.sgml : 20210301
20210301190544
ACCESSION NUMBER: 0001140361-21-006730
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210225
FILED AS OF DATE: 20210301
DATE AS OF CHANGE: 20210301
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: SCHADE CHRISTIAN S
CENTRAL INDEX KEY: 0001214496
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39069
FILM NUMBER: 21700428
MAIL ADDRESS:
STREET 1: MEDAREX
STREET 2: 707 STATE ROAD
CITY: PRINCETON
STATE: NJ
ZIP: 08540
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Aprea Therapeutics, Inc.
CENTRAL INDEX KEY: 0001781983
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 535 BOYLSTON STREET
CITY: BOSTON
STATE: MA
ZIP: 02116
BUSINESS PHONE: 6095104718
MAIL ADDRESS:
STREET 1: 535 BOYLSTON STREET
CITY: BOSTON
STATE: MA
ZIP: 02116
4
1
form4.xml
FORM 4
X0306
4
2021-02-25
0001781983
Aprea Therapeutics, Inc.
APRE
0001214496
SCHADE CHRISTIAN S
535 BOYLSTON STREET
BOSTON
MA
02116
true
true
Chairman & CEO
Common Stock
2021-02-25
4
A
0
77000
0
A
77160
D
Common Stock
2021-02-25
4
A
0
88500
0
A
176660
D
Common Stock
1000
I
By adult child
Common Stock
1000
I
By adult child
Common Stock
1000
I
By adult child
Common Stock
1000
I
By adult child
Common Stock
1000
I
By adult child
Common Stock
1000
I
By adult child
Common Stock
5000
I
By spouse
Stock Option (right to Buy)
6
2021-02-25
4
A
0
329000
0
A
2031-02-25
Common Stock
329000
329000
D
These shares represent restricted stock units which were granted on February 25, 2021, and which will vest and be settled in common stock as follows: (i) 25,666 shares on February 25, 2022, (ii) 25,667 shares on February 25, 2023 and (iii) 25,667 shares on February 25, 2024, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions.
These shares represent restricted stock units which were granted on February 25, 2021, and which will vest and be settled in common stock as follows: (i) 29,500 shares on August 25, 2021, (ii) 29,500 shares on February 25, 2022 and (iii) 29,500 shares on August 25, 2022, subject to the reporting person's continued employment through and including the applicable vesting dates and subject to acceleration under certain conditions.
Twenty-five percent of these options vest on February 25, 2022, with the remaining options vesting ratably over the following 36 months, subject to the reporting person's continued employment through and including the applicable vesting date and subject to acceleration under certain conditions.
The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, or for any other purpose.
/s/ Scott M. Coiante, attorney-in-fact
2021-03-01